At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Temozolomide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Temozolomide, Bavituximab, and 1 other intervention for Glioblastoma. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
This research study is studying a combination of drugs with radiation as a possible treatment for Glioblastoma. The drugs involved in this study are: * Bavituximab * Temozolomide
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartSep 2017
Primary CompletionAug 2022
TodayJul 2026
First PostedMay 4, 2017
Enrollment StartSep 13, 2017
Primary CompletionAug 31, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.2 years ago
Interventions
Temozolomidedrug
Temozolomide causes cell death and shrinks and kills the cancer cells
Bavituximabdrug
Bavituximab may activate (cause) the immune system to attack the cancer cells
Radiationradiation
Radiation causes cell death and shrinks and kills the cancer cells.